MHRA updates biosimilar guidance to allow interchangeability between products

RAPS

7 November 2022 - The UK’s MHRA has updated its 2021 guidance on biosimilars to allow interchangeability between biosimilars if they use the same reference medicinal product.

On 6 November, the British regulatory agency updated a 2021 document titled Guidance on the licensing of biosimilar products. It has expanded the interchangeability section of the document to account for biosimilars that have the same reference product.

Read Regulatory Affairs Professional Society article

Michael Wonder

Posted by:

Michael Wonder